Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Related Post
10 December, 2025
Shaping the future: How TROG’s Emerging Investigators group is breaking down barriers for new researchers
SPECIAL INTEREST GROUP IN FOCUS: 10 December 2025 Dr
9 December, 2025
TROG’s inaugural Km’s for Cancer Research brings community together to support our work
LATEST NEWS: 9 December 2025 As we wrap up